Retour
Retour

Alexis Vandier

Chief Executive Officer
  • management team

Alexis served as Vice-President – Global Asset Lead at Ipsen, heading their efforts to build a leading oncology platform, including their lead tyrosine kinase inhibitor (Cabometyx®, cabozantinib) which Alexis helped launch and reach its full commercial potential in various solid tumor indications and across 40 countries. Alexis also managed partnerships with Exelixis in the U.S., as well as with Roche and BMS (co-development in combination with nivolumab and atezolizumab).

Alexis’ broad international and proven leadership experience were acquired over the last 20 years in various pharma positions. First at Sanofi where he spent 11 years in Corporate Strategy and Business Development, in Finance and Marketing, then 12 years spent at Ipsen working directly with Marc de Garidel in different global roles in Strategy, Business Development, Alliance management and Innovation/Marketing across multiples geographies (EU, Asia and U.S.). Alexis also became General Manager of Ipsen France where he accelerated the development of Ipsen around medical, market access and external affairs, driving successful launches in oncology and rare diseases.

Alexis is a graduate of Ecole Centrale de Lyon and holds a master’s degree in engineering from the University of Economics, Lyon II.